Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Liknande verk

• Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
  av: Ennio Giulio Favalli, et al.
  Utgiven: (2022-05-01)
• Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
  av: Andrea Favalli, et al.
  Utgiven: (2022-06-01)
• Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
  av: Francesca Romana Spinelli, et al.
  Utgiven: (2022-01-01)
• Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis
  av: Ennio Giulio Favalli, et al.
  Utgiven: (2020-12-01)
• Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients
  av: Gilberto Cincinelli, et al.
  Utgiven: (2024-09-01)